Research programme: anticancer vaccines - Suzhou Kintor Pharmaceuticals
Latest Information Update: 28 Aug 2022
Price :
$50 *
At a glance
- Originator Suzhou Kintor Pharmaceuticals
- Class Cancer vaccines
- Mechanism of Action Immunostimulants; Programmed cell death 1 receptor antagonists; Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for research development in Cancer in China
- 01 Jul 2018 Early research in Cancer in China (unspecified route)